Iowa Institute of Human Genetics

  • CYP2C19 for Clopidogrel Efficacy

    CYP2C19 Video Graphic

     Information for Health Care Providers

    • Pharmacogenetics or pharmacogenomics involves using a patient’s genetic information to help inform health care providers on patient drug therapies. A patient’s DNA variation can affect how they respond to certain therapies.
    • The IIHG Pharmacogenomics initiative developed a genetic test for clopidogrel (or Plavix®) sensitivity. The gene being tested is CYP2C19. DNA sequence variation in the CYP2C19 gene can result in altered enzyme activity and reduced effectiveness of clopidogrel.
    • In 2010, the FDA released a Black Box Warning about the effects of CYP2C19 variants that reduce its enzyme function, resulting in a higher risk of heart attack, stroke and cardiovascular death, due to the reduced therapeutic effect of the drug. The FDA recommended health care professionals consider genetic testing for CYP2C19.
    • The goal of the presentation at right is to provide health care providers with information regarding a an IIHG Pharmacogenetic test for CYP2C19 Gene variants that influence patient response to clopidogrel (Plavix®).